

14 February 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Outcome of Board Meeting held on 14 February 2022

Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9 September 2015

Dear Sir/Madam,

With reference to the above subject, and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company held today i.e., Monday, 14 February 2022, the Board of Directors of the Company, inter-alia, discussed, considered and approved the following:

- a) Un-audited financial results (both standalone and consolidated) for the quarter ended 31 December 2022, Limited Review Reports thereon, as on 31 December 2022 (**Enclosed Annexure - I**);
- b) Approved the proposal for acquisition of 100% equity stake in water and wastewater management company, Enzotech Solutions Private Limited ("Enzotech"), a private limited company, incorporated under the Companies Act, 1956, bearing Corporate Identity Number U41000TN2006PTC059620, with its registered office at 4, Kuppusamy Street, Off Old Mahabalipuram Road, Karapakkam, Chennai - 600097, from its existing shareholders and promoters, at an acquisition price as may be determined by Independent Registered Valuer in terms of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations 2018 ("SEBI ICDR Regulations");
- c) Approved the proposal to pay the 100% consideration for acquisition of (Enzotech) by way of issuance of such number of fully paid-up equity shares of Banka BioLoo Limited on preferential basis to the shareholders of the Enzotech, i.e., by way of 100% share swap, at such price as determined in accordance with SEBI ICDR Regulations; and
- d) Approved the proposal to sell the equity shares held by Banka BioLoo Limited in Banka Earth Foundation, (a Section 8 Company), which is wholly-owned subsidiary of Banka BioLoo Limited.


Requisite details in term of SEBI Circular CIR/CFD/CMD/4/2015 dated 9 September 2015 w.r.t., items b, c and d are enclosed herewith as **Annexures II, III and IV**.

The Company shall continue to make necessary disclosures upon fixing relevant date, determination of pricing criteria, and upon approval of notice of the Extra-ordinary General Meeting for seeking approval of shareholders for the aforesaid preferential issue, and conclusion of sale of the equity shares held by Banka BioLoo Limited in Banka Earth Foundation.

The meeting commenced at 3.30 PM and concluded at 8.25 PM.
This is for your information and records

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Office





Independent Auditor's Review Report on Quarterly Unaudited Standalone and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of **Banka BioLoo Limited**,

We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **BANKA BIOLOO LIMITED** for the quarter and nine months ended December, 2021 ("the statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular'), including the manner in which it is to be disclosed, or that it contains any material misstatements.

For PRSV & Co LLP
Chartered Accountants
Firm Registration No. S200016


Y. Venkateswarlu
Partner
M. No. 222068



Place: Hyderabad
Date: 14 February 2022
UDIN: 2222068ACBJKI7626

BANKA BIOLOO LIMITED

Unaudited STANDALONE Statement of Financial Results for the quarter ended 31 December 2021

(Rs. In Lakhs)


S. No	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited
1	Income						
	Gross Revenue from operations	1152.43	1192.98	840.39	3260.87	2440.47	3,566.53
	Less:Duties & Taxes	(147.01)	(161.69)	(81.24)	(421.16)	(357.33)	(520.77)
	Revenue from Operations	1005.42	1031.29	759.16	2839.71	2083.14	3,045.76
	Other operating revenue						-
	Other income	13.88	9.26	14.34	35.19	27.27	57.61
	Total Income	1019.31	1040.55	773.50	2874.90	2110.41	3,103.37
2	Expenses						
	Cost of materials consumed	223.03	298.08	204.71	668.64	421.05	702.22
	Changes in inventories of finished goods & work-in-progress	(25.60)	(61.48)	(81.45)	(94.16)	(128.37)	(321.13)
	Employee benefits expense	478.53	445.98	290.70	1273.73	910.11	1,302.45
	Finance costs	48.86	46.75	34.15	136.75	102.61	151.45
	Depreciation and amortisation expense	25.86	20.68	13.59	66.34	39.46	59.73
	Other expenses	192.04	206.92	275.38	606.81	590.09	1,021.65
	Total expenses	942.73	956.92	737.08	2658.11	1934.95	2,916.37
3	Profit/(loss) before tax	76.58	83.63	36.43	216.79	175.46	187.00
4	Tax expense						
	(1) Current tax	19.15			19.15	33.70	-
	(2) Taxes for earlier years						(19.29)
	(3) MAT Credit						-
	(4) Deferred tax	4.67	(5.66)	(0.79)	(9.61)	(7.95)	(14.36)
	Total Tax expense	23.81	-5.66	-0.79	9.54	25.75	(33.64)
5	Profit after tax	52.77	89.29	37.22	207.25	149.71	220.64
	Other comprehensive income						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations						27.16
	Income tax effect on items that will not be reclassified to						(6.65)
	Other comprehensive income for the year	-	-	-	-	-	20.51
	Total comprehensive income for the year	52.77	89.29	37.22	207.25	149.71	241.15
6	Paid up equity share capital (Face value Rs. 10/- each)	1028.11	1028.11	1028.11	1028.11	1028.11	1,028.11
7	Earnings per share						
	Basic and Diluted Earnings per share (in Rs.)	0.51	0.87	0.36	2.02	1.46	2.15
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

 For PRSV & Co. LLP
 Chartered Accountants
 FRN No. S-200016

 Y. Venkateswarlu
 Partner
 M.No.222068

 Place: Hyderabad
 Date: 14.02.2022

FOR & ON BEHALF OF BOARD OF DIRECTORS

 Vishal Murarka
 CEO & Executive Director
 DIN: 06729485


Notes:

1. The above unaudited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14 February 2022.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter and nine months ended 31 December 2021 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31st March 2021.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
7. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 31.12.2021	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.42	
	Total	1,262.70	1192.21	-

8. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
9. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka BioLoo Limited


Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14 February 2022



Independent Auditor's Review Report on Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
Board of Directors of **Banka BioLoo Limited**,

We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **BANKA BIOLOO LIMITED** (The "Holding Company") and its subsidiary (The Holding Company and its subsidiaries and its associate together referred to as the "Group") for the quarter and nine months ended 31 December 2021 a ("the statement"), being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').

This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants of India, other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is Limited primarily to inquiries of the Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly we do not express an audit opinion.

The Statement includes the results of the following entities.

Subsidiary

Banka Earth Foundation

Associate

Sai Banka SPV Private Limited

Sustainable Sanitation Industry Association

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular'), including the manner in which it is to be disclosed, or that it contains any material misstatements.

The accompanying statement includes the unaudited interim financial results and other financial information of 1 wholly owned subsidiary whose unaudited interim financial results include total

T. Vaid

revenues of Rs. 80,873 and total net profit after tax of Rs. 5,358 and other comprehensive income of Rs. Nil and total comprehensive income of Rs. 5,358 for the quarter ended 31 December, 2021 as considered in the consolidated unaudited financial results. These interim financial results and other financial information are unaudited and have been furnished to us by the management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this wholly owned subsidiary, is based solely on that unaudited financial statement/financial information furnished by the Management.

For PRSV & Co LLP

Chartered Accountants

Firm Registration No. S200016





Y. Venkateswarlu

Partner

M. No. 222068

Place: Hyderabad

Date: 14 February 2022

UDIN: 22222068ACBTNN5182

BANKA BIOLOO LIMITED

Unaudited CONSOLIDATED Statement of Financial Results for the quarter ended 31 December 2021

(Rs. In Lakhs)

S. No	Particulars	Quarter ended			Nine Months ended		Year ended
		31.12.2021 Unaudited	30.09.2021 Unaudited	31.12.2020 Unaudited	31.12.2021 Unaudited	31.12.2020 Unaudited	31.03.2021 Audited
1	Income						
	Gross Revenue from operations	1,152.43	1,192.98	840.39	3,260.87	2,440.5	3,566.53
	Less:Duties & Taxes	(147.01)	(161.69)	(81.24)	(421.16)	(357.33)	-520.77
	Revenue from Operations	1,005.42	1,031.29	759.16	2,839.71	2,083.1	3,045.76
	Other operating revenue	-	-	-	-	-	-
	Other income	14.69	9.26	14.35	36.00	27.3	57.62
	Total Income	1,020.11	1,040.55	773.50	2,875.71	2,110.41	3,103.38
2	Expenses						
	Cost of materials consumed	223.03	298.08	204.71	668.64	421.0	702.22
	Changes in inventories of finished goods & work-in-progress	(25.60)	(61.48)	(81.45)	(94.16)	(128.37)	-321.13
	Employee benefits expense	478.53	445.98	290.70	1,273.73	910.1	1,302.45
	Finance costs	48.86	46.75	34.15	136.75	102.6	151.45
	Depreciation and amortisation expense	25.86	20.68	13.59	66.34	39.5	59.73
	Other expenses	192.79	206.92	275.38	607.57	590.1	1,021.65
	Total expenses	943.48	956.92	737.08	2,658.86	1,934.95	2,916.37
3	Share of profit/(loss) of Associates	(0.20)	(0.93)	-	(1.75)	-	(0.17)
4	Profit/(loss) before tax	76.43	82.69	36.43	215.10	175.46	186.84
5	Tax expense						
	(1) Current tax	19.15	-	-	19.15	33.7	-
	(2) Taxes for earlier years	-	-	-	-	-	-19.29
	(3) MAT Credit	-	-	-	-	-	-
	(4) Deferred tax	4.67	-5.66	-0.79	-9.61	-8.0	-14.36
	Total Tax expense	23.81	-5.66	-0.79	9.54	25.75	(33.64)
6	Profit after tax	52.62	88.35	37.22	205.56	149.71	220.48
	Other comprehensive income						
	<i>Items that will not be reclassified to profit and loss</i>						
	Remeasurement of post-employment benefit obligations						27.16
	Income tax effect on items that will not be reclassified						-6.65
	Other comprehensive income for the year						20.51
	Total comprehensive income for the year	52.62	88.35	37.22	205.56	149.71	240.99
	Attributable to						
	Shareholders of the Company	52.62	88.35	37.22	205.56	149.71	240.99
	Non controlling interest	-	-	-	0.00	0.00	0.00
7	Paid up equity share capital (Face value Rs. 10/- each)	1,028.1	1,028.1	1,028.1	1,028.1	1,028.1	1,028.11
8	Earnings per share						
	Basic and Diluted Earnings per share (in Rs.)	0.51	0.86	0.36	2.00	1.46	2.14
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

FOR & ON BEHALF OF BOARD OF DIRECTORS

For PRSV & Co. LLP
Chartered Accountants
FRN No. S-200016

Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 14.02.2022



Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Notes:

1. The above statement of Audited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 14 December 2021.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Banka Earth Foundation	Subsidiary
Sai Banka SPV Pvt Ltd	Associate
Sustainable Sanitation Industry Association	Associate

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For **Banka BioLoo Limited**



Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 14 February 2022

14 February 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: Banka

Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 31 December 2021


Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter ended 31 December 2021.

This is for your information and necessary records.

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary and Compliance Officer

STATEMENT OF DEVIATION(S) OR VARIATION(S) UNDER REGULATION 32(1) OF SEBI (LODR) REGULATIONS, 2015

In reference to the compliance under Regulation 32(1)(a) & (b) of SEBI (LODR) Regulations, 2015, as required under regulation 32(8) of SEBI (LODR) Regulations, 2015, the Company hereby submits to National Stock Exchange, statement of deviation(s) or variation(s) for the quarter ended 31 December 2021.

- a) **Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable;**

We, hereby, inform you that there was no deviation in the utilisation of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1)(a) of SEBI (LODR) Regulations, 2015.

- b) **Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilisation of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable, and the actual utilisation of funds**

We, hereby, inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018, or explanatory statement to the notice of the Extra-Ordinary Meeting dated 16 November 2017, issued for Initial Public offering of Securities, as per regulation 32(1)(b) of SEBI (LODR) Regulations, 2015.

Thank you!

For Banka BioLoo Limited



Vishal Murarka
CEO & Executive Director
DIN:06729485

Annexure - II

Details of Target Company

No.	Particulars	Details
1	Name of the target entity, details in brief, such as size, turnover etc.	Enzotech Solutions Private Limited Address: 4, Old Mahabalipuram Road, Karappakkam, Chennai - 600097 Turnover (as on 31.03.2021): Rs. 424.20 lakhs
2	Whether the acquisition would fall within related party transaction, and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof, and whether the same is done at "arm's length".	No, it is independent company.
3	Industry to which the entity being acquired belongs	Enzotech is among the leading providers of water treatment, sewage treatment, and effluent treatment solutions in India. Enzotech supplies the entire range of water treatment plants, including DM plants, water treatment plants, ultrafiltration and RO. Enzotech has deep expertise, with 425+ running plants in wastewater treatment, and has worked with prestigious clients across India. Pre-approvals from leading government bodies, architects, and plumbing consultants.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The present acquisition/ investment allows Company to enter new markets of wastewater and effluent treatment by offering of new products/ services. Enzotech will be 100% wholly-owned subsidiary of the Company, and it will be run independently, to offer products and services in the chosen segments.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time for completion of acquisition	31 March 2022

7	Nature of Consideration - whether cash consideration or share swap and details of the same	100% shares swap						
8	Cost of acquisition or the price at which the shares are acquired.	Indicative 100% equity value will be approx. Rs. 4.5 crores, and will be determined by a valuation report of an Independent Registered Valuer, as required in terms of SEBI ICDR Regulations, 2018.						
9	Percentage of shareholding/ control acquired and/ or number of shares acquired.	Post transaction, 100% of Enzotech will be owned by the Company.						
10	Brief background about the entity acquired, in terms of products/ lines of business acquired, date of incorporation, history of last 3 years' turnover, country in which the acquired entity has presence and any other significant information (in brief).	Enzotech Solutions Private Limited is an engineering, procurement and construction (EPC) company, focused on the wastewater treatment sector. Enzotech started operations in 2006, and has been managed by the present owners since 2011. Last three years' turnover: <table border="1"> <thead> <tr> <th>FY 2018-19</th><th>FY 2019-20</th><th>FY 2020-21</th></tr> </thead> <tbody> <tr> <td>781.45</td><td>569.77</td><td>424.20</td></tr> </tbody> </table> (values in Rs. lakhs)	FY 2018-19	FY 2019-20	FY 2020-21	781.45	569.77	424.20
FY 2018-19	FY 2019-20	FY 2020-21						
781.45	569.77	424.20						

This is for your information and records.

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Office

Annexure - III
Issuance of securities

No.	Particulars	
1	Type of Securities	Fully paid-up equity shares of the Company, proposed to be issued towards 100% consideration for acquisition of (Enzotech) by Banka BioLoo Limited, by way of issuance of such number of equity shares of Banka BioLoo Limited on preferential basis to the shareholders of the Enzotech i.e., by way of 100% share swap, at such price as determined in accordance with SEBI ICDR Regulations.
2.	Type of Issuance	Preferential Allotment
3.	Total number of securities proposed to be issued, or the total amount for which the securities will be issued	The approximate acquisition price is Rs. 4.5 crores.
4.	Names of Investors	Names of proposed Allottees • Ajay Jain & Ritu Jain • K Mahalingam • K Ravishankar • K Ramkumar • N Balasubramanian • A Sekar • Acsys Investments Pvt Ltd • Ajay Jain
5	Post allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors	a) Outcome of the subscription shall be intimated post allotment of proposed equity shares; b) Issue price/allotment price - as may be determined in accordance with SEBI ICDR Regulations, 2018; c) Number of proposed Allottees 8

This is for your information and records.

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Office

Annexure - IV


Sale of 100% equity shares held by the Company in subsidiary of the Listed Entity

No.	Particulars	
1.	The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year	Nil / Not applicable
2.	Date on which the agreement for sale has been entered into	No written agreement
3.	The expected date of completion of sale/disposal	28 February 2022
4.	Consideration received from such sale/disposal	As per valuation report, but not less than the face value.
5.	Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof;	Mrs Namita Banka and Ms Smriti Banka (belonging to the promoter/ promoter group) Mrs. Namita Banka is the promoter and Managing Director, and Ms Smriti Banka is her daughter.
6.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arms' length"?	Yes, and the same shall be done at arms' length basis i.e., based up on valuation report obtained from a registered valuer.
7.	Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.	Not applicable, as it is proposed sell the 100% equity shares of the Company.

This is for your information and records

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary & Compliance Office